The prognostic implication of visual acuity at the time of uveal melanoma diagnosis
Open Access
- 24 November 2022
- journal article
- research article
- Published by Springer Nature in Eye
- Vol. 37 (11) , 2204-2211
Abstract
Background: Visual outcomes after primary tumour treatment of uveal melanoma (UM) have been investigated repeatedly. This study evaluates the correlation between best-corrected visual acuity (BCVA) before treatment with clinicopathological factors and patient survival. Subjects/Methods: Pre-treatment BCVA was examined in relation to tumour dimensions and location, and survival in a retrospective cohort of 1809 patients who underwent plaque brachytherapy. BCVA was also correlated to tumour histological factors in a second cohort of 137 enucleated eyes. Results: The mean BCVA of the tumour eye prior to plaque brachytherapy was LogMAR 0.42 (SD 0.46). Patients with low BCVA (LogMAR ≥ 1.00) did not differ in age (p = 0.19) and had similar frequency of ciliary body involvement (p = 0.99) but had tumours with greater apical thickness (p < 0.0001), greater diameter (p < 0.0001) and shorter distance to the optic disc and fovea (p < 0.0001). There were no significant relations between low BCVA and any of 13 examined tumour histological factors at a Bonferroni-corrected significance level (p > 0.004). Patients with low BCVA had greater incidence of UM-related mortality in competing risk analysis (p = 0.0019) and shorter overall survival (p < 0.0001). Low BCVA was also associated with increased hazard ratio (HR) for UM-related mortality in univariate analysis (HR 1.5, 95% confidence interval 1.2 to 1.9), but not in multivariate analysis with tumour size and location as covariates. Conclusions: UM patients with low BCVA before primary tumour treatment have a worse prognosis, likely related to increased tumour dimensions. Future studies should examine the prognostic significance of BCVA in relation to macula-involving retinal detachment and genetic factors.Keywords
Funding Information
- Royal Swedish Academy of Sciences (ME2019-0036)
- Cancerfonden (20 0798 Fk)
- Karolinska Institutet (2021-01131)
- Stiftelsen Kronprinsessan Margaretas Arbetsnämnd för Synskadade (157)
This publication has 61 references indexed in Scilit:
- Frequent Mutation of BAP1 in Metastasizing Uveal MelanomasScience, 2010
- Competing risk analysis using R: an easy guide for cliniciansBone Marrow Transplantation, 2007
- Optic Nerve Invasion of Uveal Melanoma: Clinical Characteristics and Metastatic PatternInvestigative Ophthalmology & Visual Science, 2006
- Ruthenium Brachytherapy for Uveal Melanoma, 1979–2003Survival and Functional Outcomes in the Swedish PopulationOphthalmology, 2005
- Using the KM visual acuity chart for more reliable evaluation of amblyopia compared to the HVOT methodActa Ophthalmologica Scandinavica, 2004
- Very Long-Term Prognosis of Patients with Malignant Uveal MelanomaInvestigative Ophthalmology & Visual Science, 2003
- Visual acuity results after plaque radiotherapy: Author replyOphthalmology, 2001
- Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma I. visual acuity after 3 years COMS report no. 16Ophthalmology, 2001
- Histopathologic characteristics of uveal melanomas in eyes enucleated from the collaborative ocular melanoma study COMS report no. 6American Journal of Ophthalmology, 1998
- Reassessment of the PAS patterns in uveal melanomaBritish Journal of Ophthalmology, 1997